From March 1994 to September 1997, 30 patients with hematological malignancies (12 ANLL, 10 CML, four ALL and four multiple myeloma) received HLA-identical allogeneic bone marrow transplants with the marrow graft selectively depleted of CD4 ؉ lymphocytes and the CD8
receiving a transplant in more advanced phases of the disease (87.5 ؎ 11.6% vs 72.9 ؎ 16.5%; P = 0.44). The incidence of mixed chimerism assessed by PCR was 34%. Nineteen patients are alive between 2 and 43 months post-transplant, the probability of overall survival being 57.8 ؎ 10.4%. Our data indicate that this method of selective T cell depletion is very effective in preventing acute GVHD in high risk patients, particularly when used in combination with post-transplant CsA ؉ MTX.
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Ex vivo depletion of T lymphocytes from the donor marrow is the most effective method to prevent graft-versus-host disease, but it is uniformly associated with increased risk of graft failure and leukemic relapse. Thus the reduction in morbidity and mortality due to GVHD is not translated into an increase in disease-free survival. [1] [2] [3] [4] During the last few years, several methods of selective or partial T cell depletion have been described [5] [6] [7] [8] [9] [10] [11] [12] in an attempt to eliminate the potential effectors of GVHD exclusively and to leave some alloreactive T lymphocytes in the donor marrow that are able to reduce graft failure and maintain a graft-versusleukemia reaction. Although the clinical results of these selective T cell depletion protocols generally are better than those of exhaustive T cell depletion, the goal of a marked reduction in GVHD without a concomitant loss of graft enhancing and GVL effects is still to be achieved.
Experimental evidence in animal models 13 as well as preliminary clinical results [14] [15] [16] suggest that the presence of low doses of CD8 ϩ T lymphocytes in donor bone marrow depleted of CD4 ϩ T cells can ensure engraftment. In fact, Gallardo et al 17 have recently reported no graft failure and a low incidence of severe acute GVHD in 12 chronic myeloid leukemia patients with high risk for developing GVHD who received allogeneic bone marrow depleted of CD4 ϩ lymphocytes with the content of CD8 ϩ cells adjusted to 0.25 ϫ 10 6 /kg; similarly, Verdonck et al 11 reported a 100% engraftment with a fixed low number of T cells, that obviously contained CD8 ϩ lymphocytes, in the marrow graft. In contrast, in four series with CD8 ϩ T cell depletion, [5] [6] [7] [8] the reported incidence of primary graft failure ranges from 4.5 to 10%, which is not different from that reported with complete T cell depletion. Therefore, it seems clear that allogeneic engraftment is dependent on the presence of even very low numbers of donor CD8 ϩ cells in the marrow graft.
We present here the clinical results of 30 patients with high risk of GVHD that received allogeneic HLA-identical bone marrow depleted of CD4 ϩ lymphocytes containing a fixed number of 1 ϫ 10 6 /kg CD8 ϩ cells. The aim of the work was to evaluate this method of partial T cell depletion in terms of GVHD incidence, engraftment and relapse rate. In order to assess the impact of additional prophylaxis on GVHD incidence, patients were randomly assigned to receive either cyclosporin A or cyclosporin A plus methotrexate.
Materials and methods

Patients
Between March 1994 and September 1997, 30 patients with hematological malignancies were entered into the study, after giving written informed consent. The clinical characteristics of the patients are shown in Table 1 . Twenty-four patients received bone marrow from HLA-identical sibling donors, and the remaining six from a matched unrelated donor (MUD). All patients were considered as high risk for developing GVHD by at least one of the following criteria: (1) patient age Ͼ35 years; [18] [19] [20] (2) donor age Ͼ35 years;
18-20 (3) donor multiparity; 21 (4) unrelated donor. 22 Ten patients had one risk factor (always patient age Ͼ35 or marrow from MUD), 13 patients had two risk factors, and seven had three risk factors.
Conditioning regimens
All patients received conventional conditioning regimens that were as follows: 19 patients were conditioned with cyclophosphamide (60 mg/kg/day ϫ 2 days) and total body 
Supportive care
Patients were treated in either laminar air flow or positivepressure reverse isolation rooms, and received routine antibiotic prophylaxis with ciprofloxacin 500 mg p.o. every 12 h and fluconazole 200 mg p.o. daily, starting on the day of admission. All patients but one received G-CSF (Filgrastim; Amgen Roche, Thousand Oaks, CA, USA) at a dose of 5 g/kg/day, starting on day 0 (four patients) or ϩ7 (25 patients), until they reached an ANC Ͼ1000/l for 3 consecutive days. As part of a randomized trial, 14 patients received human intravenous immunoglobulin at a dose of 150 mg/kg every other week until day ϩ90, and monthly thereafter during the first year post transplant. Patients received filtered (leukocyte-poor) red blood transfusions and platelet concentrates. All blood components were irradiated (20 Gy) to prevent transfusion-related GVHD.
GVHD prophylaxis and treatment
In order to assess the role of two regimens of additional pharmacological prophylaxis of the GVHD, patients were randomly assigned to receive either cyclosporin A at an initial dose of 3 mg/kg/day i.v. (n = 15), or cyclosporin A (initial dose 1.5 mg/kg/day) plus methotrexate (15 mg/m 2 day ϩ1, and 10 mg/m 2 days ϩ3, ϩ6 and ϩ11) followed by folinic acid (n = 15). In both groups, as soon as the patient was capable of taking oral nutrition, cyclosporin A was switched to an every 12 h oral administration schedule and maintained for 3-6 months. The six patients receiving marrow from MUD were randomised separately, and so three patients were assigned to each arm.
The diagnosis and grading of GVHD was established according to previously defined criteria. 23 Acute GVHD grade I or more was treated with methylprednisolone 1-2 mg/kg /day. Patients were considered at risk of developing chronic GVHD when they were alive at day ϩ150 without evidence of relapse. Chronic GVHD was treated with prednisone 0.5-1 mg/kg every other day and cyclosporin A.
Bone marrow processing
Donor bone marrow was obtained by multiple aspirations from the iliac crests, either at our hospital or at various collection centers. Mononuclear cells were isolated by gradient density centrifugation on Ficoll-Hypaque using a COBE 2991 (Cobe, Lakewood, IL, USA). The recovered mononuclear cells were washed three times and resuspended in saline containing 1% human serum albumin at a concentration of 2-3 ϫ 10 7 cells/ml. A sample was taken to determine the percentages of CD2, CD34, CD4 and CD8 by flow cytometric analysis as described later. Depletion of CD4 ϩ and CD8 ϩ T cells was carried out by immunomagnetic separation using Dynabeads M-450 CD4 and M-450 CD8 (Dynal, Oslo, Norway) in two consecutive steps. First, marrow MNC were incubated with Dynabeads M-450 CD4 (ratio beads:target cell 5:1) for 30 min at 4°C on a rotator. After incubation, magnetic separation was accomplished on the MaxSep Magnetic Cell Separator (Baxter, Deerfield, IL, USA). A sample of the depleted product was obtained to determine the efficacy of depletion and the percentage of CD8 ϩ cells. In a second step, an aliquot of the cellular suspension that contained 1 ϫ 10 6 CD8 ϩ cells/kg patient body weight was reserved without further manipulation, and the rest of the marrow underwent a second procedure of depletion by the same method using Dynabeads M-450 CD8.
Once the efficacy of the CD8 depletion was assessed by flow cytometry, the two cellular fractions were mixed and immediately infused to the patient through a central venous access.
Flow cytometry
CD2, CD4, CD8 and CD34 surface markers were determined by direct immunofluorescence using the following FITC-labeled antibodies: anti-Leu 5b (CD2), anti-Leu 3a (CD4) anti-Leu 2a (CD8) and HPCA-2 (CD34) purchased from Becton Dickinson (San Jose, CA, USA). After staining according to the manufacturer's instructions, the cells were analyzed using a EPICS-Profile Cytometer (Coulter, Hialeah, FL, USA). The percentages of positive cells were calculated by subtracting the respective number of isotypelabeled negative control cells. The sensitivity of flow cytometric analysis was 0.1% according to previous experiments.
Progenitor cell assay
The CFU-GM progenitor cell assay was performed in semisolid medium consisting of Iscove's modified Dulbecco's medium (IMDM), 0.9% methylcellulose, 20% fetal calf serum and 12% human placental conditioned medium. Cultures were plated in duplicated in 35 mm Petri dishes, incubated at 37°C in 5% CO 2 in air, and scored on day 7.
Analysis of chimerism
High molecular weight DNA was extracted from peripheral blood mononuclear cells obtained from the donor and recipient before transplant using a salting out procedure. 24 After transplant, DNA was isolated from the peripheral blood of the patients to allow determination of chimerism by a polymerase chain reaction amplification method (PCR).
For PCR amplification, we used specific primers designed to flank the repeat units of the following human minisatellite regions: D1S80, 33.6, 33.1, YNZ-22, APO-B, g3, DXS52 and 3ЈHVR. The sequence of the primers and conditions for each reaction have been described elsewhere. [25] [26] [27] [28] All products of amplification were electropheresed in tris-borate buffer on 1-3% agarose gels which were stained with ethidium bromide. The gels were photographed by ultraviolet transilumination. We defined a minisatellite locus as being informative if analysis of recipient and donor samples prior to BMT showed a unique band for the recipient and a unique band for the donor, or showed a unique band for the recipient only.
To assess the sensitivity of this method, DNA from several donors and recipients were mixed in the following proportions of host DNA: 25, 10, 5, 3.5, 2, 1.5, 1, 0.5 and 0.1%. Each DNA mixture was subjected to PCR analysis. Sensitivity was considered as the lowest proportion of host DNA in the mixtures for which host DNA could be detected. The sensitivity of the different minisatellites ranged between 0.5 and 1% (data not shown).
Patients who exhibited complete donor hematopoiesis with all markers tested at all times were defined as donor or complete chimeras. Patients who exhibited mixed populations of donor and host cells on more than one occasion with at least two different markers after day ϩ45 or when the recipient was transfusion independent were considered to exhibit mixed chimeras.
Statistical analysis
The median duration of follow-up for the patient population was 21 months (range 2-43 months). Cumulative actuarial probabilities of engraftment, GVHD, remaining in complete remission and overall survival were calculated using the Kaplan-Meier method. 29 Comparisons of time to event distributions were made using the log rank test. The Cox regression model 30 was used to investigate factors associated with clinically significant grades of GVHD.
Results
Ex vivo bone marrow treatment
The mean initial percentages of CD4 ϩ and CD8 ϩ cells were 28.4 Ϯ 8.0% and 28.9 Ϯ 9.0%, respectively. After depletion procedures these percentages fell to 0.03 Ϯ 0.01% and 0.42 Ϯ 1.08%, respectively. In 29 cases after CD4 depletion and in 26 after CD8 depletion no residual positive cells were detected by flow cytometry after subtraction of the isotype control. In these cases, a percentage of 0.09% residual positive cells was assumed for the purpose of calculation. The calculated purging efficiency for CD4 ϩ cells is 2.73 Ϯ 0.26 log and 2.51 Ϯ 0.57 for CD8 ϩ lymphocytes. Non-specific loss of hematopoietic progenitors was 59.8 Ϯ 23.1% for CFU-GM, and 57.5 Ϯ 24.2% for CD34 ϩ cells. The cellular composition of the final infused graft is shown in Table 2 .
Engraftment
Two patients were not evaluable for engraftment due to leukemia post transplant in one case and to early death in the other. No case of primary graft failure was observed,
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The cumulative probabilities of myeloid and platelet engraftment are shown in Figure 1 . As can be seen, there was no significant difference in the probability of engraftment between patients receiving CsA or CsA ϩ MTX.
We have not found statistically significant differences in the probability of primary engraftment between patients receiving or not receiving TBI in the conditioning, nor between those receiving or not receiving hyperfractionated TBI (data not shown).
Two patients among the 28 evaluable presented late graft failure. The first was a female diagnosed with ANLL-M 7 with extensive myelofibrosis, who received marrow transplant in partial remission, and after initial engraftment developed pancytopenia on day ϩ165 and died from Candida krusei sepsis. The second was a male with CML who received marrow from an unrelated donor and developed graft failure on day ϩ94; he received unmanipulated BMT from the original donor, and after initial engraftment with complete donor chimera, on day ϩ240 he showed autologous hematopoiesis and relapse of his CML.
Graft-versus-host disease
Fourteen patients (50% of 28 evaluable) had no signs of acute GVHD, eight (28%) had grade I and six (21%) had grade II acute GVHD. Patients with grade I or II acute GVHD were treated with steroids for a median time of 50 days (range 13-64) for those receiving CsA alone, and 25 days (range 12-40) for those receiving CsA ϩ MTX. No patient developed grades III-IV GVHD, and all six patients with grade II responded completely to steroids. The cumulative probability of developing clinically significant aGVHD was 25.9 Ϯ 9.6% (Figure 2 ). We did not find any significant difference in the incidence of acute GVHD between patients receiving or not receiving TBI, or receiving or not receiving hyperfractionated TBI in the conditioning (data not shown).
Among the 15 patients who had received additional prophylaxis with CsA five (33%) developed grade II aGVHD, whereas only one patient among those receiving CsA ϩ MTX (6%) had this complication. The actuarial incidence of grade II aGVHD was 50.6 Ϯ 17.8% in the CsA group vs 6.7 Ϯ 6.4% in the CsA ϩ MTX group ( Figure 3) ; this difference was statistically significant (log rank = 4.50, P = 0.03). The multivariate analysis of factors potentially associated with aGVHD (including dose of infused T cells, number of high risk criteria, sibling donor or MUD, diagnosis and disease's status, and additional GVHD prophylaxis) revealed that the unique factor associated with lower incidence of aGVHD was the combination of CsA and MTX as additional prophylaxis (P = 0.03). Eighteen patients were evaluable for chronic GVHD. Limited cGVHD developed in two patients and extensive forms of the disease in three patients. All but one responded completely to immunosuppressive therapy, and there were no deaths attributable to either cGVHD or its treatment. The actuarial probability of developing cGVHD in this series is 31.8 Ϯ 12.5%, and that of presenting an extensive form is 20.8 Ϯ 11.4% (Figure 4) . Among nine evaluable patients receiving CsA the actuarial incidence of cGVHD is 66.7 Ϯ 24.8%, whereas among the nine receiving CsA ϩ MTX it is only 11.2 Ϯ 10.4%; this difference, however, did not reach statistical signification (P = 0.07), probably because of the small number of patients. None of the factors analyzed had a significant association with cGVHD in the multivariate analysis. 
Relapse
Seven patients have relapsed. Two patients with ANLL who were not in complete remission at the time of BMT relapsed on days ϩ20 and ϩ70, respectively, and one patient with ANLL-M 4 transplanted in first CR relapsed also on day ϩ70. Four patients with CML relapsed in months ϩ5, ϩ8, ϩ12 and ϩ30 post transplant; the remaining six CML patients are in complete molecular remission with bcr/abl persistently negative. The 3.5 year actuarial probability of remaining in complete remission for the entire patient population was 53.6 Ϯ 17.3%, with a mean remission duration of 30.1 Ϯ 3.9 months ( Figure 5 ). For patients with acute leukemia receiving a transplant in first complete remission the 3 year probability of being in remission was 87.5 Ϯ 11.6%, and for those transplanted in advanced phases of their disease (second or subsequent complete remission, or nonremission) was 72.9 Ϯ 16.5% ( Figure 6) ; there was no statistically significant difference between these two groups of patients (P = 0.44).
Survival
Nineteen patients are alive between 2 and 43 months post transplant; the overall 3.5 year actuarial survival is 57.8 Ϯ 10.4% (Figure 7) . 72.9 ± 16.5
Figure 6
Actuarial probability of remaining in complete remission for patients with acute leukemia transplanted in first complete remission (--) or in more advanced phases of the disease (---). Log rank test, P = 0.44. Eleven patients died, four due to leukemic relapse (leukemic mortality rate 13.3%) and seven due to transplant-related complications: bacterial infection three cases, fungal infection one case, hepatic veno-occlusive disease two cases and interstitial pneumonitis one case (transplantrelated mortality rate 23.3%). No deaths attributable to GVHD were observed.
Chimerism
Data concerning hematopoietic chimerism are available in 23 patients. Fifteen of them are complete hematopoietic chimeras, and eight (34%) developed mixed chimerism after being complete chimeras for periods ranging from 1 to 20 months.
No patient among the 15 that are complete chimeras have relapsed; by contrast, five out of eight patients with mixed chimerism relapsed. There is a strong association between mixed chimerism and relapse in patients with CML (four relapses among five mixed chimeras, P = 0.02 by Fischer's exact test), but not in patients with acute leukemia (one relapse among three mixed chimeras, P = 0.27).
Discussion
In this study we analyzed the impact of a model of partial T cell depletion and post-transplant immunosuppression on GVHD incidence, engraftment and leukemic relapse in 30 patients with high risk of developing GVHD. Our results demonstrate that depletion of CD4 ϩ lymphocytes plus reduction of the CD8 ϩ T cell content in the bone marrow graft, in combination with cyclosporin A or cyclosporin A plus methotrexate, is extremely effective in preventing GVHD in high risk patients.
It is well known that complete depletion of T cells in the graft is the most effective method for GVHD prophylaxis, with a reported incidence of this complication of only 10% without the need for additional inmunosuppression. 2, 31, 32 However, with the new strategies of T cell depletion consisting of the selective elimination of determined T cell subsets, the incidence of clinically significant aGVHD is higher, ranging from 18 to 28% for recipients of HLA-identical marrow without special risk factors, [5] [6] [7] [8] [9] [10] [11] and from 33 to 63% for recipients of marrow from an unrelated donor. 8, 9, 12 The low incidence of 21% grade II aGVHD without any case of grade III-IV in our series is only comparable with that reported by Verdonk et al 11 (28% grade II exclusively) in standard risk patients receiving marrow grafts with 1 ϫ 10 5 T cells/kg. With this sole exception, all the published experiences with partial or selective models of T cell depletion have reported some incidence of severe grade III-IV acute GVHD, that varies between 5 and 20% after CD8 ϩ depletion, 5-8 9% using a CD5 ϩ or CD6 ϩ depletion in standard risk patients, 9,10 and reaches 37% in recipients of CD8-depleted marrow from unrelated donors. 8 It is possible that the use of steroids in our patients as soon as the first sign of acute GVHD appeared, could also have abrogated the progression of the disease to a more severe grade. Although, in fact, many factors can influence both the incidence and the severity of GVHD and can therefore result in marked differences between groups of patients, our results as well as those of the above mentioned series suggest a pivotal role for CD4 ϩ T lymphocytes in the pathogenesis of clinical acute GVHD as has been previously demonstrated at the experimental level. [33] [34] [35] After exhaustive T cell depletion, there is probably no need for additional immunosuppression as prophylaxis for GVHD. However, data from the IBMTR demonstrated that post-transplant methotrexate plus cyclosporin A reduced the likelihood of acute GVHD after T cell-depleted transplantation whereas this effect is not detected with methotrexate or cyclosporin A alone. 1 Our data are in agreement with these results, and it may be of important clinical relevance for two reasons: first, until now, there were no convincing data in the literature regarding the role of posttransplant immunosuppression in recipients of marrow partial or selectively depleted of T cells; and second, the low incidence and severity of acute GVHD, particularly in the group receiving CsA ϩ MTX with only 5% of patients having grade II GVHD, supports the evaluation of this schedule in patients with even higher risk of GVHD, such as recipients of marrow from HLA-mismatched donors.
No patient in this series developed primary graft failure, and the rate of engraftment was comparable to that seen after unmodified allogeneic marrow transplants. Gallardo et al 17 have also recently reported a 100% rate of primary engraftment using a method of T cell depletion which is identical to that reported here, except for a lower dose of CD8 ϩ lymphocytes in the graft corresponding to 0.25 ϫ 10 6 /kg. In sharp contrast are the results of three series reporting their results with a model of CD8 ϩ selective depletion [5] [6] [7] in which the incidence of primary graft failure, ranging from 5 to 10% is not different from that reported with complete T cell depletion. All these findings, considered as a whole, strongly suggest an important role for CD8 ϩ donor lymphocytes in the engraftment of allogeneic marrow, as had been previously proven in experimental murine models. 13 It is difficult to evaluate the actual impact of this method of selective T cell depletion on leukemic relapse due to the heterogeneity of the group. However, it seems that, at least for the 16 patients with acute leukemia, the probability of remaining in complete remission is comparable with that reported after conventional unmodified allogeneic transplant, even for those receiving BMT in advanced phases of their disease. Data from the literature regarding the relapse rate after T cell-depleted transplants for acute leukemia are controversial: whereas several trials of both complete and selectively T cell-depleted transplants have reported increased rates of leukemia relapse, 1, 10, 36 others have found the risk of disease recurrence to be similar to that after conventional BMT. 37, 38 It is possible that many factors, such as different intensity of pretransplant chemotherapy and conditioning regimens as well as differences in the proportion of high risk patients in each series, may have contributed to these apparently contradictory results. Following standard preparative regimens, the incidence of relapse in our series is 12% for patients with acute leukemia in first CR and 27% for those in advanced phase of their disease, including three patients transplanted whilst not in remission.
In contrast to the results observed in recipients of T celldepleted marrow for acute leukemia, most such studies of CML patients have revealed a dramatically increased risk of relapse, 1, 39, 40 and this finding is consistent with a particularly important role for donor lymphocytes in maintaining remission in CML. Among the 10 patients with CML in chronic phase in this series, four relapsed between 5 and 30 months post transplant, and although the number of patients is too small to draw any conclusions, it seems that the post-transplant relapse rate for patients with CML is increased with our method of selective T cell depletion, as it is after complete T cell depletion. Some experimental data have indicated that the GVL effect against CML is mainly exerted by donor CD4 ϩ lymphocytes, 41, 42 and the elimination of this cellular subset with our method of selective depletion as well as after exhaustive T cell depletion, may be responsible for the loss of the GVL effect that leads to the high relapse rate observed. Consistent with this concept, are the results of four series of selective depletion of CD8 ϩ lymphocytes, [5] [6] [7] [8] in which no patient with CML has relapsed. In contrast, Gallardo et al 17 have recently reported a 0% incidence of relapse in 12 patients with CML transplanted with marrow depleted of T cells by a method identical to that reported in our series, except for a lower dose of infused CD8 ϩ cells. We have no convincing explanation for the difference in the relapse rates between our CML patients and those reported by Gallardo, but the small number of patients as well as differences in risk factors between both series may account for this.
In conclusion, the method of selective T cell depletion that we present here, in combination with post-transplant immunosuppression, reduces dramatically the incidence and severity of acute GVHD, particularly in patients receiving the combination of CsA plus MTX, without adversely influencing either the ability of primary engraftment or the relapse rate in acute leukemia patients, but not in CML. These results support the continued application of the method in patients with acute leukemia at high risk of GVHD and provides rationale for its use in BMT from nonfully-matched donors.
